Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 6,240,000 shares, an increase of 33.3% from the April 30th total of 4,680,000 shares. Based on an average daily trading volume, of 2,080,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.2% of the company's stock are sold short.

Takeda Pharmaceutical Stock Down 0.4%

NYSE TAK traded down $0.06 on Thursday, hitting $14.98. 1,690,087 shares of the stock traded hands, compared to its average volume of 1,934,305. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average of $14.65 and a 200 day moving average of $14.08. Takeda Pharmaceutical has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a market capitalization of $47.65 billion, a P/E ratio of 37.44, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, analysts expect that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds have recently modified their holdings of the company. Belpointe Asset Management LLC bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth $191,000. Fortis Capital Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at $191,000. Focus Partners Wealth boosted its position in shares of Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock valued at $1,230,000 after purchasing an additional 3,239 shares during the period. Goldman Sachs Group Inc. increased its stake in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock worth $2,911,000 after buying an additional 59,442 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.